SEC Form 4 · accession 0001179110-17-002953
ABBOTT LABORATORIES · ABT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Roger Bird
Officer — Senior Vice President
Period of report
Feb 17, 2017
Accepted (ET)
Feb 22, 2017 · 5:59 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000001800
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common shares without par valueF1 | Feb 17, 2017 | A | 13,307 | $0.00 | A | 63,910 | D | |
| Common shares without par value | Feb 21, 2017 | F | 727 | $44.69 | D | 63,183 | D | |
| Common shares without par value | Feb 21, 2017 | S | 219 | $44.91 | D | 62,964 | D | |
| Common shares without par value | Feb 21, 2017 | S | 100 | $44.995 | D | 62,864 | D | |
| Common shares without par value | Feb 22, 2017 | M | 11,030 | $26.6973 | A | 73,894 | D | |
| Common shares without par value | Feb 22, 2017 | M | 1,873 | $26.1976 | A | 75,767 | D | |
| Common shares without par value | Feb 22, 2017 | S | 9,936 | $45.02 | D | 65,831 | D | |
| Common shares without par value | Feb 22, 2017 | S | 700 | $45.03 | D | 65,131 | D | |
| Common shares without par value | Feb 22, 2017 | S | 100 | $45.031 | D | 65,031 | D | |
| Common shares without par value | Feb 22, 2017 | S | 1,500 | $45.035 | D | 63,531 | D | |
| Common shares without par value | Feb 22, 2017 | S | 400 | $45.04 | D | 63,131 | D | |
| Common shares without par value | Feb 22, 2017 | S | 100 | $45.041 | D | 63,031 | D | |
| Common shares without par value | Feb 22, 2017 | S | 167 | $45.045 | D | 62,864 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option (right to buy)F2 | $44.40 | Feb 17, 2017 | A | 92,032 | A | Feb 17, 2018 | Feb 16, 2027 | Common shares | 92,032 | 92,032 | D |
| Option (right to buy)F3 | $26.6973 | Feb 22, 2017 | M | 11,030 | D | Feb 15, 2011 | Feb 14, 2018 | Common shares | 11,030 | 0 | D |
| Option (right to buy)F3 | $26.1976 | Feb 22, 2017 | M | 1,873 | D | Mar 31, 2011 | Mar 30, 2018 | Common shares | 1,873 | 0 | D |
Explanation of responses
- F1These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes.
- F2Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 30,678 on 02/17/2018, 30,677 on 02/17/2019, and 30,677 on 02/17/2020.
- F3Employee stock option granted pursuant to the Abbott Laboratories 1996 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.
Remarks
The sale transactions on February 21, 2017, were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).